Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Regarding “Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma”

Regarding “Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma” Cardiovasc Intervent Radiol (2017) 40:1479 DOI 10.1007/s00270-017-1707-0 LETTE R T O T HE EDI T OR Regarding ‘‘Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma’’ Zhongzhi Jia Received: 22 April 2017 / Accepted: 19 May 2017 / Published online: 26 May 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 We read with great interest the recent article by Chan et al. may bias the results. Secondly, there were a total of 3 [1]. The authors concluded that radioembolization with patients with macrovascular invasion according to Table 1, yttrium-90 microspheres appears to be a promising treat- but there were 4 patients with macrovascular invasion ment option for patients with unresectable combined hep- according to Figure 2B, which causes serious confusion to atocellular–cholangiocarcinoma, and poor performance the readers. status and the presence of macrovascular invasion were Compliance with Ethical Standards identified as predictors of reduced survival after radioem- bolization. However, we would like to elaborate on the Conflicts of interest The author declares that he has no competing treatments pre- and post-radioembolization of the patients. interests. Firstly, there were a total of 10 patients included in this study, and many of them had received http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png CardioVascular and Interventional Radiology Springer Journals

Regarding “Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma”

Download PDF
1 page

Regarding “Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma”

Abstract

Cardiovasc Intervent Radiol (2017) 40:1479 DOI 10.1007/s00270-017-1707-0 LETTE R T O T HE EDI T OR Regarding ‘‘Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma’’ Zhongzhi Jia Received: 22 April 2017 / Accepted: 19 May 2017 / Published online: 26 May 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 We read with great interest the recent...
Loading next page...
 
/lp/springer_journal/regarding-yttrium-90-radioembolization-for-unresectable-combined-WFN9Yo1RuO

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Subject
Medicine & Public Health; Imaging / Radiology; Cardiology; Nuclear Medicine; Ultrasound
ISSN
0174-1551
eISSN
1432-086X
DOI
10.1007/s00270-017-1707-0
Publisher site
See Article on Publisher Site

Abstract

Cardiovasc Intervent Radiol (2017) 40:1479 DOI 10.1007/s00270-017-1707-0 LETTE R T O T HE EDI T OR Regarding ‘‘Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular–Cholangiocarcinoma’’ Zhongzhi Jia Received: 22 April 2017 / Accepted: 19 May 2017 / Published online: 26 May 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 We read with great interest the recent article by Chan et al. may bias the results. Secondly, there were a total of 3 [1]. The authors concluded that radioembolization with patients with macrovascular invasion according to Table 1, yttrium-90 microspheres appears to be a promising treat- but there were 4 patients with macrovascular invasion ment option for patients with unresectable combined hep- according to Figure 2B, which causes serious confusion to atocellular–cholangiocarcinoma, and poor performance the readers. status and the presence of macrovascular invasion were Compliance with Ethical Standards identified as predictors of reduced survival after radioem- bolization. However, we would like to elaborate on the Conflicts of interest The author declares that he has no competing treatments pre- and post-radioembolization of the patients. interests. Firstly, there were a total of 10 patients included in this study, and many of them had received

Journal

CardioVascular and Interventional Radiology – Springer Journals

Published: May 26, 2017

There are no references for this article.